Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

Blood (2017) 130 (Supplement 1): 153.

https://doi.org/10.1182/blood.V130.Suppl_1.153.153

Published: 2017

Journal Articles

Standardized IGH-Based Next-Generation Sequencing for MRD Detection in Follicular Lymphoma

Christiane Pott, MD, PhD, Henrik Knecht, PhD, Arved Herzog, Elisa Genuardi, Michael Unterhalt, MD PhD, Barbara Mantoan, Irene Dogliotti, Wolfgang Hiddemann, MD PhD, Mario Boccadoro, Dietrich Herrmann, Michael Kneba, MD, Anton W Langerak, Nikos Darzentas, Patricia Groenen, Monika Brüggemann, MD, Eva Hoster, Marco Ladetto, Simone Ferrero

Blood (2017) 130 (Supplement 1): 1491.

https://doi.org/10.1182/blood.V130.Suppl_1.1491.1491

Published: 2017

Journal Articles

Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma – Results from Randomized Trials of the European MCL Network

Eva Hoster, PhD, Andreas Rosenwald, MD, Francoise Berger, MD PhD, Heinz-Wolfram Bernd, Sylvia Hartmann, Christoph Loddenkemper, Thomas Barth, Nicole Brousse, Stefano Pileri, Grzegorz Rymkiewicz, Roman Kodet, Michael Unterhalt, MD, Johanna C. Kluin-Nelemans, Olivier Hermine, MD PhD, Wolfgang Hiddemann, MD PhD, Martin H. Dreyling, Wolfram Klapper, MD

Blood (2014) 124 (21): 2977.

https://doi.org/10.1182/blood.V124.21.2977.2977

Published: 2014

Journal Articles

Rituximab Maintenance (MR) for Patients with Mantle Cell Lymphoma (MCL) – a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Liat Vidal, MDMSc, Anat Gafter-Gvili, MD, Martin Dreyling, Michele Ghielmini, MD, Michael Unterhalt, MD, Pia Raanani, MD, Ofer Shpilberg, MD, Ron Ram, MD, Ronit Gurion, MD

Blood (2014) 124 (21): 4466.

https://doi.org/10.1182/blood.V124.21.4466.4466

Published: 2014

Journal Articles

Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study

Marie-Hélène Delfau-Larue, MD PhD, Klapper Wolfram, MDPhD, Francoise Berger, Fabrice Jardin, MD PhD, Josette Briere, MD, Catherine Thieblemont, MD PhD, Pierre Feugier, MD PhD, Corinne Haioun, MD, Gilles Andre Salles, MD PhD, Vincent Ribrag, MD, Rene-Olivier Casasnovas, MD, Michael Unterhalt, MD, Martin Dreyling, Christiane Pott, MD PhD, Elizabeth Macintyre, MD PhD, Olivier Hermine, MD PhD, Eva Hoster, PhD

Blood (2014) 124 (21): 1625.

https://doi.org/10.1182/blood.V124.21.1625.1625

Published: 2014

Journal Articles

MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network

Christiane Pott, M..D, PhD, Elizabeth Macintyre, MD PhD, Marie-Helene Delfau-Larue, MD PhD, Vincent Ribrag, MD, Michael Unterhalt, MD, Michael Kneba, MD PhD, Wolfgang Hiddemann, MD, Martin Dreyling, MD PhD, Olivier Hermine, MD PhD, Eva Hoster, PhD

Blood (2014) 124 (21): 147.

https://doi.org/10.1182/blood.V124.21.147.147

Published: 2014

Journal Articles

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Eva Hoster, PhD, Michael Unterhalt, MD, Michael Pfreundschuh, Michael Hallek, MD, Roswitha Forstpointner, Bernd Metzner, Hermann Einsele, Jürgen Krauter, MD, Ulrich Dührsen, Wolf-Dieter Ludwig, Josef Birkmann, Norma Peter, Wolfram Klapper, MD, Martin H. Dreyling, Wolfgang Hiddemann, MD PhD

Blood (2014) 124 (21): 1752.

https://doi.org/10.1182/blood.V124.21.1752.1752

Published: 2014

Journal Articles

Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network ( MCL net )

Blood (2010) 116 (21): 110.

https://doi.org/10.1182/blood.V116.21.110.110

Published: 2010

Journal Articles

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Jan Braess, MD, PhD, Karsten Spiekermann, MD, PhD, Christian Buske, MD, PhD, Peter Staib, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Andreas Gruneisen, MD, Christa Sauerland, PhD, Michael Unterhalt, MD, PhD, Michael Fiegl, MD, Bernhard Wormann, MD, PhD, Wolfgang Kern, MD, PhD, Achim Heinicke, PhD, Wolfgang Berdel, MD, PhD, Thomas Büchner, MD, PhD, Wolfgang Hiddemann, MD, PhD

Blood (2007) 110 (11): 295.

https://doi.org/10.1182/blood.V110.11.295.295

Published: 2007

Journal Articles

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

Friederike Schneider, Eva Hoster, PhD, Marietta Rottenkolber, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, MD, Michael Unterhalt, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Jan Braess, MD, Achim Heinecke, PhD, Wolfgang E. Berdel, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3482.

https://doi.org/10.1182/blood.V110.11.3482.3482

Published: 2007

Journal Articles

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Stephanie Schneider, PhD, Friederike Schneider, Annika Dufour, PhD, Gudrun Mellert, Evelyn Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard J. Wormann, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3486.

https://doi.org/10.1182/blood.V110.11.3486.3486

Published: 2007

Journal Articles

Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.

Oliver Weigert, MD, Christoph von Schilling, MD PhD, Mathias J. Rummel, MD PhD, Antonio Pezzutto, MD PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD PhD, Martin H. Dreyling, MD PhD

Blood (2007) 110 (11): 4501.

https://doi.org/10.1182/blood.V110.11.4501.4501

Published: 2007

Journal Articles

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Martin H. Dreyling, MD, Roswitha Forstpointner, MD, Hans-Peter Boeck, MD, Roland Repp, MD, Hannes Wandt, MD, Christiane Pott, MD, John Francis Seymour, MD, Bernd Metzner, MD, Annette Haenel, MD, Tanja Lehmann, MD, Frank Hartmann, MD, Hermann Einsele, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 2769.

https://doi.org/10.1182/blood.V108.11.2769.2769

Published: 2006

Journal Articles

Dose-Dense Induction (Sequential-HAM) in Primary Acute Myeloid Leukemia - A Pilot Study of the AML-CG.

Jan Braess, MD, PhD, Peter Staib, MD, PhD, Wolf D. Ludwig, MD, PhD, Bernhard J. Wormann, MD, PhD, Andreas Reichle, MD, PhD, Wolfgang Berdel, MD, PhD, Thomas Buchner, MD, PhD, Andreas Gruneisen, MD, Christoph Schmid, MD, Christian Schmid, MD, PhD, Wolfgang Kern, MD, PhD, Karsten Spiekermann, MD, PhD, Michael Fiegl, MD, Michaela Feuring-Buske, MD, PhD, Stefan Bohlander, MD, PhD, Achim Heinicke, Christ Sauerland, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2006) 108 (11): 1997.

https://doi.org/10.1182/blood.V108.11.1997.1997

Published: 2006

Journal Articles

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Karsten Spiekermann, MD, Annika Dufour, PhD, Gudrun Mellert, Evelin Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, MD, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard Josef Wormann, MD, Thomas Buchner, MD, Wolfgang Hiddemann, MD, Acute Myeloid Leukemia Cooperative Group (AMLCG)

Blood (2006) 108 (11): 805.

https://doi.org/10.1182/blood.V108.11.805.805

Published: 2006

Journal Articles

Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Christian Buske, MD, Michael Kneba, MD, PhD, Eva Lengfelder, MD, Michael Pfreundschuh, MD, Wolf-Dieter Ludwig, MD, Ullrich Graeven, MD, Michael Hallek, MD, Martin Dreyling, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2006) 108 (11): 482.

https://doi.org/10.1182/blood.V108.11.482.482

Published: 2006

Journal Articles

Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.

Wolfgang Hiddemann, MD, PhD, Eva Hoster, MSc, Christian Buske, MD, PhD, Martin Dreyling, MD, PhD, Michael Kneba, MD, PhD, Michael Hallek, MD, PhD, Eva Lengfelder, MD, Hannes Wandt, MD, PhD, Michael Unterhalt, MD

Blood (2006) 108 (11): 483.

https://doi.org/10.1182/blood.V108.11.483.483

Published: 2006

Journal Articles

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Rudolf Weide, MD, Georg Hess, MD, Hubert Koeppler, MD, Jochen Heymanns, MD, Joerg Thomalla, MD, Ali Aldaoud, MD, Christoph Losem, MD, Stefan Schmitz, MD, Ursula Haak, MD, Christoph Huber, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, Martin Dreyling, MD

Blood (2006) 108 (11): 2480.

https://doi.org/10.1182/blood.V108.11.2480.2480

Published: 2006

Journal Articles

Improvement of Overall Survival in Mantle Cell Lymphoma during the Last Decades.

Annina Herrmann, MSc, Eva Hoster, MSc, Martin Dreyling, MD, PhD, Michael Unterhalt, MD, Günter Brittinger, MD, PhD, Wolfgang Hiddemann, MD, PhD

Blood (2006) 108 (11): 2446.

https://doi.org/10.1182/blood.V108.11.2446.2446

Published: 2006

Journal Articles

High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.

Oliver Weigert, MD, Eckhart Weidmann, MD, Rudolf Mueck, MD, Martin Bentz, MD, Christoph von Schilling, MD, Robert Rohrberg, MD, Kathleen Jentsch-Ullrich, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, Martin H. Dreyling, MD

Blood (2006) 108 (11): 2449.

https://doi.org/10.1182/blood.V108.11.2449.2449

Published: 2006

NARROW

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

Standardized IGH-Based Next-Generation Sequencing for MRD Detection in Follicular Lymphoma

Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma – Results from Randomized Trials of the European MCL Network

Rituximab Maintenance (MR) for Patients with Mantle Cell Lymphoma (MCL) – a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study

MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG.

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not Appropriate for Autologous Stem Cell Transplantation - Final Analysis of a Phase II Trial of the European MCL Network.

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Dose-Dense Induction (Sequential-HAM) in Primary Acute Myeloid Leukemia - A Pilot Study of the AML-CG.

NPM-1, but Not FLT3-ITD Mutations Predict Early Blast Cell Clearance and CR Rate in Patients with Normal Karyotype AML or High-Risk Myelodysplastic Syndrome (MDS).

Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.

High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicentre Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).

Improvement of Overall Survival in Mantle Cell Lymphoma during the Last Decades.

High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only